MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel ...
Independent Analysis Examines ColonBroom GLP-1 Booster Ingredient Transparency, Non-Prescription Supplement Category Context, ...
Gene therapy treatments for rare diseases are being developed, but getting them out of the lab has proved challenging.
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving ...
Interesting Engineering on MSN
Chinese scientists build mini womb on a chip to study human embryo implantation
For decades, scientists have struggled to study this moment in humans because of ethical restrictions and limited access to ...
January 10, 2026 - PRESSADVANTAGE - WhiteSands Alcohol & Drug Rehab Ocala has published a new medically focused ...
Plant City, Florida - January 09, 2026 - PRESSADVANTAGE - WhiteSands Alcohol & Drug Rehab Plant City has published ...
Martin Makary, commissioner of the Food and Drug Administration, on the push against ultra processed foods and added sugar, ...
A compassionate, face-to-face approach ensures immediate care, privacy, and support We strive to reach the young women ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...
Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...
Johnson & Johnson today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback